Prostate Cancer Diagnosis, Transformed by EXACT IMAGING TECHNOLOGY




As Featured In:

Exact Imaging was incorporated in Ontario in 2013, and is the world’s leader in high resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate.


Exact Imaging’s ExactVu™ micro-ultrasound system, operates up to 29 MHz and enables a new level of resolution compared to conventional urological ultrasound systems. The ExactVu system supports both transrectal and transperineal procedures while maintaining the standard workflow for performing conventional systematic prostate biopsies.

Exact Imaging has received global interest and recognition throughout its history.


Micro-ultrasound and its potential as a lower-cost alternative to MRI in the diagnosis of prostate cancer have been the topic of numerous publications and presentations at leading urology meetings. Several clinical studies have demonstrated comparable detection rates for prostate cancer diagnosis with the multiparametric MRI-guided prostate biopsy. In 2022, a 3-arm randomized controlled trial is underway to evaluate the role of 29MHz micro-ultrasound in guiding prostate biopsy in men with clinical suspicion of prostate cancer.

Exact Imaging has received investments from numerous government based programs, including Health Technology Exchange (“HTX”, Ontario, $750,000), IRAP (Canada $50,000), FedDev Investing in Business
Innovation (“IBI”, Ontario, $980,000). The company has also benefited from dividual, corporate, and angel investors and bank loans.


Exact Imaging was awarded Life Science Ontario’s 2019 Life Science Company of the Year. In the extensive ecosystem of Ontario-based innovation, manufacturing and commercialization expertise that comprises Exact Imaging’s peer group, this recognition of the way the company has redefined the diagnosis of prostate cancer with significant benefits for patients and clinicians was truly an honour for the company.

In May 2020, Exact Imaging entered an exclusive worldwide distribution agreement with France-based EDAP TMS SA, the manufacturer of the Focal One high intensity focused ultrasound (HIFU) treatment solution. The combination of these technologies represents a complete end-to-end solution, from diagnosis through treatment using minimally invasive therapy solutions to prostate cancer patients.


This partnership has provided an exciting opportunity for Exact Imaging to reach new customers worldwide through EDAP’s network of subsidiary companies and distribution partners provide, and sales of the ExactVu system and the EV29L transducer have been at their all-time high since this partnership formed.

The future is bright as we look forward to the continued opportunity to improve men’s health and prostate cancer diagnosis.

Company Information

Other INNOVATE® Ecosystems